Tandem Diabetes Care said its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor.
The company has initiated an early access program in the U.S., and intends to scale availability in the second half of 2025.
The FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the Tandem t:slim mobile app, providing users with multiple, convenient ways to access their current glucose trend.
The t:slim X2 insulin pump is powered by Control-IQ+ technology, the latest generation of Tandem's advanced hybrid closed-loop algorithm, which adjusts insulin every 5 minutes based on predicted glucose values.
“This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott’s FreeStyle Libre 3 Plus sensors worldwide,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “We look forward to expanding access to our t:slim X2 users outside of the U.S. beginning later this year.”
